Injectable Azithromycin Formulation for Lower Feline Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibiotic formulations, particularly those containing azithromycin, pose a high risk of toxicity and adverse effects, especially in felines, necessitating the development of compositions with lower toxicity while maintaining efficacy.
Innovation Solution
A composition comprising a hydrated form of azithromycin, a suitable solvent such as triacetin or caprylic/capric triglycerides, and an excipient like KOLLIPHOR™, formulated for injection, which reduces toxicity and allows a single dose to effectively treat infections in small subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If azithromycin is used to treat bacterial infections in cats, then infection treatment efficacy is improved, but toxicity and adverse effects increase
Solution Approach 1:
The patent changes the physical and chemical parameters of the azithromycin formulation by using a specific solvent system (triacetin and caprylic/capric triglycerides) and controlling pH (6.5-7.5) to reduce toxicity while maintaining efficacy. The hydrated form of azithromycin (7.0% w/w) in this optimized formulation achieves lower tissue concentrations and reduced adverse effects compared to conventional formulations.
Solution Approach 2:
The patent employs a composite formulation system combining multiple components: hydrated azithromycin, triacetin solvent, caprylic/capric triglycerides, and excipients like KOLLIPHOR™. This composite material approach creates a synergistic formulation that improves drug delivery and reduces toxicity through the combined properties of its constituents.
2Adaptability or versatility
If conventional macrolide formulations are administered, then broad-spectrum antibacterial coverage is achieved, but gastrointestinal side effects and cardiac risks increase
Solution Approach 1:
The patent modifies formulation parameters including pH (6.5-7.5), solvent composition (triacetin and caprylic/capric triglycerides), and drug concentration (7.0% w/w azithromycin) to reduce gastrointestinal irritation and cardiac risks while preserving broad-spectrum activity against susceptible bacteria.
Solution Approach 2:
The patent uses specific excipients and solvent systems as intermediary substances that mediate between the drug and the animal's body. KOLLIPHOR™ and the triglyceride-based solvents act as intermediaries that improve drug solubility and reduce direct irritation to gastrointestinal tissues and cardiac systems.
3Ease of operation
If azithromycin is formulated for injection in small subjects, then treatment convenience is improved, but formulation stability and safety become more challenging
Solution Approach 1:
The patent optimizes formulation parameters specifically for small subjects including pH control (6.5-7.5), solvent selection (triacetin and caprylic/capric triglycerides), and concentration (7.0% w/w azithromycin) to ensure both stability and safety in felines and other small animals, enabling convenient single-injection treatment.
Solution Approach 2:
The patent develops a composite injectable formulation combining hydrated azithromycin with specific solvents and excipients that maintain physical and chemical stability in small-volume injections for small subjects, ensuring safety and efficacy in this challenging application area.
Data Source
AI summary
Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.